AMG 579

Drug Profile

AMG 579

Latest Information Update: 14 Oct 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Amgen
  • Class Antipsychotics; Small molecules
  • Mechanism of Action Phosphodiesterase 10A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Schizoaffective disorder; Schizophrenia

Most Recent Events

  • 14 Oct 2015 No recent reports on development identified - Phase-I for Schizoaffective disorder in USA (PO)
  • 14 Oct 2015 No recent reports on development identified - Phase-I for Schizophrenia in USA (PO)
  • 30 Jun 2012 Amgen terminates a phase I trial in Schizophrenia and Schizoaffective disorder in USA (NCT01568203)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top